22:40 , Sep 13, 2018 |  BC Week In Review  |  Clinical News

BMS's IPF therapy discontinued after Phase II safety signal

Data published in Chest showed that a twice-daily 600 mg dose of BMS-986020 from Bristol-Myers Squibb Co. (NYSE:BMY) significantly slowed the rate of decline in forced vital capacity (FVC) vs. placebo in the Phase II...
15:53 , Mar 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Spinal cord injury (SCI) Cell culture and mouse studies suggest promoting LPPR1 expression or inhibiting LPAR1 could help treat SCI. In primary mouse cortical neurons subjected to scrape injury, overexpression of LPPR1 increased regeneration of...
03:51 , Nov 19, 2016 |  BioCentury  |  Strategy

Adding on in fibrosis

Bristol-Myers Squibb Co.’s deal to license worldwide rights to Nitto Denko Corp.’s antifibrotic siRNA therapy gives the pharma one of industry’s broadest fibrosis pipelines - and the ability to test multiple combinations. BMS now owns...
07:00 , Oct 15, 2015 |  BC Innovations  |  Finance

Public-Private Partnership Roundup

PPP activity was down slightly in 3Q15 compared with the previous quarter, with 61 partnerships announced during that span. Big pharmas and biotechs continue to pair up with public and academic institutions at a high...
01:31 , Sep 1, 2015 |  BC Extra  |  Company News

BMS gets option to buy fibrosis company Promedior

Bristol-Myers Squibb Co. (NYSE:BMY) obtained an exclusive option to acquire Promedior Inc. (Lexington, Mass.), which would give it rights to idiopathic pulmonary fibrosis (IPF) and myelofibrosis (MF) candidate PRM-151. Promedior shareholders are eligible to receive...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Bristol-Myers, Medical University of South Carolina deal

Bristol-Myers and MUSC partnered to conduct translational research on fibrotic diseases, including scleroderma, renal fibrosis and idiopathic pulmonary fibrosis (IPF). The collaboration aims to elucidate the mechanism of fibrosis while using patient segmentation to explore...
08:00 , Feb 5, 2015 |  BC Innovations  |  Translation in Brief

Proteome atlas

It's taken over a decade to collect the data, but a group of Swedish researchers has developed the Human Protein Atlas, a tissue-based map of the human proteome that describes where every protein is expressed...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Company News

Galecto, Bristol-Myers deal

Galecto Biotech granted Bristol-Myers Squibb an exclusive option to acquire the biotech. Galecto's TD139, an inhaled galectin-3 (LGALS3) inhibitor, is in a Phase I trial to treat idiopathic pulmonary fibrosis (IPF) and other...
02:15 , Nov 4, 2014 |  BC Extra  |  Company News

BMS takes option to acquire Galecto

Bristol-Myers Squibb Co. (NYSE:BMY) obtained an exclusive option to acquire Galecto Biotech AB (Copenhagen, Denmark), which would give it rights to lead program TD139, an inhaled galectin-3 ( LGALS3) inhibitor to treat pulmonary fibrotic conditions....
07:00 , Sep 8, 2014 |  BioCentury  |  Strategy

Parsing Roche's IPF bet

InterMune Inc.'s third Phase III trial transformed it from a forgotten company with $70.3 million in 2013 sales of one Orphan product to a takeout play worth $8.3 billion to Roche. The question now is...